Leg, Foot Amputations Occurred Twice as Often in Patients Treated with Canagliflozin

The U.S. Food and Drug Administration (FDA) confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR).

Health care professionals should, before starting canagliflozin, consider factors that may predispose patients to the need for amputations. These factors include a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.

Read the FDA Drug Safety Communication

(Source: Medical Board of California)